SATB2 作为结直肠来源肿瘤的诊断标志物的作用：基于病理学的临床前瞻性研究结果。
The role of SATB2 as a diagnostic marker for tumors of colorectal origin: Results of a pathology-based clinical prospective study.
机构信息
Dept of Immunology, Genetics and Pathology, Uppsala University, 75185 Uppsala, Sweden;
出版信息
Am J Clin Pathol. 2014 May;141(5):630-8. doi: 10.1309/AJCPWW2URZ9JKQJU.
OBJECTIVES
Immunohistochemistry is an important extension to clinical information and morphology, and prevails as an invaluable tool for establishing a correct cancer diagnosis in clinical diagnostic pathology. The applicability of immunohistochemistry is limited by the availability of validated cell- and cancer-type specific antibodies, rendering an unmet need to discover, test, and validate novel markers. The SATB2 protein is selectively expressed in glandular cells from the lower gastrointestinal tract and expression is retained in a large majority of primary and metastatic colorectal cancers.
METHODS
We analyzed the expression of SATB2 in all clinical cases (n = 840), in which immunohistochemistry for detection of CK20 was deemed necessary for a final diagnosis.
RESULTS
SATB2 showed a high sensitivity (93%) and specificity (77%) to determine a cancer of colorectal origin and in combination with CK7 and CK20, the specificity increased to 100%.
CONCLUSIONS
We conclude that SATB2 provides a new and advantageous supplement for clinical differential diagnostics.
目的
免疫组织化学是对临床信息和形态学的重要扩展，是临床诊断病理学中建立正确癌症诊断的宝贵工具。免疫组织化学的适用性受到经过验证的细胞和癌症特异性抗体的可用性的限制，因此需要发现、测试和验证新的标志物。SATB2 蛋白在胃肠道下部的腺体细胞中选择性表达，并且在大多数原发性和转移性结直肠癌中保留表达。
方法
我们分析了 SATB2 在所有临床病例（n=840）中的表达，其中免疫组织化学检测 CK20 被认为是最终诊断所必需的。
结果
SATB2 对确定结直肠来源的癌症具有高灵敏度（93%）和特异性（77%），并且与 CK7 和 CK20 联合使用时，特异性增加到 100%。
结论
我们得出结论，SATB2 为临床鉴别诊断提供了一种新的有利补充。
Zotero 插件